Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family

Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family in Europe. Orion applies for approval in European Union through decentralised procedure. The review process will commence once all involved member states have validated the application. ORION CORPORATION STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25 p.m. EET Orion Corporation Timo Lappalainen President and CEO Reijo Salonen SVP, Research and Development Contact person: Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

The release as fetched from its publisher. orionpharma.com ↗